Clinical Trials for Relapsed Cancer
Advancing Childhood Cancer Therapies (ACCT) Clinic
For patients with relapsed, refractory, or recurrent cancer, early phase clinical trials may be a treatment option. Phase I and phase II clinical trials provide access to the newest, most innovative therapies to patients.
The Advancing Childhood Cancer Therapies (ACCT) Clinic is dedicated to
offering state-of-the-art therapies, advancing the science of pediatric
research, and providing personalized care to you and your family. The Clinic includes experts in each type of cancer as well as teams of subspecialists and nurses who are leaders in their respective fields. In August 2016, we joined the Children’s Oncology Group Phase 1 Consortium, one of only 21 such centers in the United States and the only one in New England.
Our currently active phase I and phase II trials for patients with relapsed, recurrent, or refractory cancer are listed below by disease – or search all of our available clinical trials.
If you have questions about which trial might be right for your child or patient, please email us at clinicaltrials@danafarberbostonchildrens.org or call us at 1-855-320-2090. We can help you navigate your options.
Phase I and II Trials for Relapsed and Refractory Cancer
- A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- Phase 1 Trial of CUDC-907 in Children and
Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or
Lymphoma
Principal Investigator Steven DuBois, MD
- A Phase 1, Open-Label, Dose-Escalation Study
of Olaratumab as a Single Agent and in Combination with Doxorubicin,
Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with
Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase I/II Study of Pembrolizumab
(MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced,
relapsed or refractory solid tumor or lymphoma
Principal Investigator Steven DuBois, MD
- PNOC 002: Safety, Phase 0, and Pilot
Efficacy Study of Vemurafenib, an oral inhibitor of BRAFV600E, in Children
and Young Adults with Recurrent/Refractory BRAFV600E or BRAF Ins T mutant
Brain Tumors
Principal Investigator Susan Chi, MD
- A Phase I Study of the Oral TRK Inhibitor
LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central
Nervous System Tumors
Principal Investigator Steven DuBois, MD
- A Phase 1/1b, Open-Label, Dose-Escalation
and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents
with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of Selinexor (KPT-330), a
Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid
Tumors, Including CNS Tumors
Principal Investigator Suzanne Shusterman, MD
- A Phase I/II, Multicenter, Open-Label,
Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in
Pediatric and Young Adult Patients with Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase II Study of the EZH2 Inhibitor
Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapse or
Refractory Synovial Sarcoma
Principal Investigator Gregory Cote, MD
- A Phase I Study of the EZH2 Inhibitor
Tazemetostat in Pediatric Subjects with Relapsed or Refractory
INI1-Negative Tumors or Synovial Sarcoma
Principal Investigator Susan Chi, MD
- Phase I-II Study of MEK162 for Children
Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors
Principal Investigator Mark Kieran, MD
- Phase I Open Label, Dose Escalation,
Monotherapy Trial of Afatinib to Determine the MTD, Safety, PK and
Efficacy of Afatinib in Children Aged 2 Years to <18 Years with
Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and Tumours
with ErbB Pathway Deregulation
Principal Investigator Mark Kieran, MD
- An Open-Label, Dose-Escalation, Phase I/II
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and
Clinical Activity of the MEK Inhibitor Trametinib in Children and
Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib
in Combination with Dabrafenib in Children and Adolescents with Cancers
Harboring V600 Mutations>
Principal Investigator Mark Kieran, MD
- A Phase II Study of Cabozantinib (XL184) for
Plexiform Neurofibromas in Subjects with Neurofibromatosis Type 1 Age 16
Years or Greater
Principal Investigator Nicole Ullrich, MD
- Phase II Study of Metronomic and Targeted
Anti-Angiogenesis Therapy for Children with Recurrent/Progressive
Medulloblastoma
Principal Investigator Mark Kieran, MD
- Open-label, Phase 2 Study of Bevacizumab in
Children and Adults with Neurofibromatosis 2 and Progressive Vestibular
Schwannomas That Are Poor Candidates for Standard Treatment with Surgery
or Radiation
Principal Investigator Nicole Ullrich, MD
- Phase I/IIa, 2-Part, Multi-Center,
Single-Arm, Open-Label Study to Determine the Safety, Tolerability and
Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to
<18 Years with Advanced BRAF V600-Mutation Positive Solid Tumors
Principal Investigator Mark Kieran, MD
Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
- A Phase 1/2 Study of Nivolumab in Children,
Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a
Single Agent and in Combination with Ipilimumab
Principal Investigator Steven DuBois, MD
- Phase 1 Trial of CUDC-907 in Children and Young
Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Principal Investigator Steven DuBois, MD
- A Phase I/II Study of Pembrolizumab (MK-3475) in
Children with advanced melanoma or a PD-L1 positive advanced, relapsed or
refractory solid tumor or lymphoma
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of Selinexor (KPT-330), a
Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors,
Including CNS Tumors
Principal Investigator Suzanne Shusterman, MD
- Phase I Study of Carfilzomib in Combination with
Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid
Tumors and Leukemias
Principal Investigator Steven DuBois, MD
- An Early Phase, Multicenter, Open-Label Study of
the Safety and Pharmacokinetics of Anti-PD-L1 Antibody (MPDL3280A) in Pediatric
and Young Adult Patients with Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD
- An Open-Label, Dose-Escalation, Phase I/II Study
to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical
Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects
with Cancer or Plexiform Neurofibromas and Trametinib in Combination with
Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
Principal Investigator Mark Kieran, MD
- A Phase I Trial of Temsirolimus in Combination
with Etoposide and Cyclophosphamide in Children with Relapsed Acute
Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
Principal Investigator Lewis Silverman, MD
Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
- A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Principal Investigator Steven DuBois, MD, MS
- A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Principal Investigator Steven DuBois, MD, MS
- A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
Principal Investigator Steven DuBois, MD
- A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Principal Investigator Steven DuBois, MD
- A Phase 1, Open-Label, Dose-Escalation Study
of Olaratumab as a Single Agent and in Combination with Doxorubicin,
Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with
Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase I Study of the Oral TRK Inhibitor
LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central
Nervous System Tumors
Principal Investigator Steven DuBois, MD
- A Phase 1/1b, Open-Label, Dose-Escalation
and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents
with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
Principal Investigator Steven DuBois, MD
- Phase I
Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide
for Children with Relapsed and Refractory Solid Tumors and Leukemias
Principal Investigator Steven DuBois, MD
- A Phase
I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and
Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with
Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase
1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor,
in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Principal Investigator Suzanne Shusterman, MD
- Phase I
Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine
the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to
<18 Years with Recurrent/Refractory Neuroectodermal Tumours,
Rhabdomyosarcoma and Tumours with ErbB Pathway Deregulation
Principal Investigator Mark Kieran, MD
- An Early Phase, Multicenter, Open-Label Study of
the Safety and Pharmacokinetics of Anti-PD-L1 Antibody (MPDL3280A) in Pediatric
and Young Adult Patients with Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD
- Phase
I Study of SF1126 For Patients with Relapsed or Refractory Neuroblastoma
Principal Investigator Suzanne Shusterman, MD
- An
Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety,
Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK
Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or
Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in
Children and Adolescents with Cancers Harboring V600 Mutations
Principal Investigator Mark Kieran, MD
- A Phase I Study of Sorafenib andCyclophosphamide and Topotecan in Patients with Relapsed and RefractoryNeuroblastoma
Principal Investigator Suzanne Shusterman, MD
- Phase I Study of Difluoromethylornithine (DFMO) and Celecoxib with Cyclophosphamide/Topotecanfor Patients with Relapsed or Refractory Neuroblastoma
Principal Investigator Suzanne Shusterman, MD
- Randomized Phase II Study of131I-MIBG vs. 131I-MIBG with Vincristine and Irinotecan vs.131I-MIBG withVorinistat for Resistant/Relapsed Neuroblastoma
Principal Investigator Suzanne Shusterman, MD
- A Phase I, Open-label, DoseEscalation Study of LDK378 in Pediatric Patients with Malignancies That Have aGenetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Principal Investigator Suzanne Shusterman, MD
- A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus or Chimeric 14.18 Antibody in Children with Refractory, Relapsed or Progressive Neuroblastoma
Principal Investigator Suzanne Shusterman
- A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 with or without Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma
Principal Investigator Suzanne Shusterman, MD
- An
Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine
(131I-MIBG) Therapy in Patients with Refractory Neuroblastoma,
Pheochromocytoma, or Paraganglioma
Principal Investigator Suzanne Shusterman, MD
Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
- A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Principal Investigator Steven DuBois, MD, MS
- A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Principal Investigator Steven DuBois, MD, MS
- A Phase
1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with
Recurrent or Refractory Solid Tumors as a Single Agent and in Combination
with Ipilimumab
Principal Investigator Steven DuBois, MD
- A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- Phase 1
Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory
Solid Tumors, CNS Tumors, or Lymphoma
Principal Investigator Steven DuBois, MD
- A Phase
I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma
or a PD-L1 positive advanced, relapsed or refractory solid tumor or
lymphoma
Principal Investigator Steven DuBois, MD
- A Phase
1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and
in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose
Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase
I Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with
Advanced Solid or Primary Central Nervous System Tumors
Principal Investigator Steven DuBois, MD
- A Phase
1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib
(RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid
Tumors and Primary CNS Tumors
Principal Investigator Steven DuBois, MD
- Phase I
Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide
for Children with Relapsed and Refractory Solid Tumors and Leukemias
Principal Investigator Steven DuBois, MD
- A Phase
I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and
Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with
Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase
1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor,
in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Principal Investigator Suzanne Shusterman, MD
- Phase I
Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine
the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to
<18 Years with Recurrent/Refractory Neuroectodermal Tumours,
Rhabdomyosarcoma and Tumours with ErbB Pathway Deregulation
Principal Investigator Mark Kieran, MD
- An Early
Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of
Anti-PD-L1 Antibody (MPDL3280A) In Pediatric and Young Adult Patients with
Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD
- An
Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety,
Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK
Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or
Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in
Children and Adolescents with Cancers Harboring V600 Mutations
Principal Investigator Mark Kieran, MD
- A Phase
I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients with
Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase
(ALK)
Principal Investigator Suzanne Shusterman, MD
- Phase I Study of Olaparib with Irinotecan
and/or Temezolomide in Adolescent and Adult Patients with
Recurrent/Metastatic Ewing’s Sarcoma Following Failure of Prior
Chemotherapy
Principal Investigator Steven
DuBois, MD
- An Open
Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine
(131I-MIBG) Therapy in Patients with Refractory Neuroblastoma,
Pheochromocytoma, or Paraganglioma
Principal Investigator Suzanne Shusterman, MD
Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
- A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Principal Investigator Steven DuBois, MD, MS
- A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Principal Investigator Steven DuBois, MD, MS
- Phase 1/2 Study of Nivolumab in Children,
Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a
Single Agent and in Combination with Ipilimumab
Principal Investigator Steven DuBois, MD
- A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- Phase 1 Trial of CUDC-907 in Children and Young
Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Principal Investigator Steven DuBois, MD
- A Phase I/II Study of Pembrolizumab (MK-3475) in
Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or
Refractory Solid Tumor or Lymphoma
Principal Investigator Steven DuBois, MD
- A Phase 1, Open-Label, Dose-Escalation Study of
Olaratumab as a Single Agent and in Combination with Doxorubicin,
Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with
Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase I Study of the Oral TRK Inhibitor
LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous
System Tumors
Principal Investigator Steven DuBois, MD
- A Phase 1/1b, Open-Label, Dose-Escalation and
Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with
Recurrent or Refractory Solid Tumors and Primary CNS Tumors
Principal Investigator Steven DuBois, MD
- An Open-label, Multi-center, Phase 2 Study of
Denosumab in Subjects with Giant Cell Tumor of Bone
Principal Investigator Katherine Janeway, MD
- A Phase 1 Study of Selinexor, a Selective XPO1
Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS
Tumors
Principal Investigator Suzanne Shusterman, MD
- A Phase
I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and
Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with
Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase II Study of the EZH2 Inhibitor
Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapse or
Refractory Synovial Sarcoma
Principal Investigator Gregory Cote, MD
- A Phase I Study of the EZH2 Inhibitor
Tazemetostat in Pediatric Subjects with Relapse or Refractory INI1-Negative
Tumors or Synovial Sarcoma
Principal Investigator Susan Chi, MD
- An Early Phase, Multicenter, Open-Label Study of
the Safety and Pharmacokinetics of Anti-PD-L1 Antibody (MPDL3280A) in Pediatric
and Young Adult Patients with Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD
- An Open-Label, Dose-Escalation, Phase I/II Study
to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical
Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects
with Cancer or Plexiform Neurofibromas and Trametinib in Combination with
Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
Principal Investigator Mark Kieran, MD
- A Phase I, Open-label, Dose Escalation Study of
LDK378 in Pediatric Patients with Malignancies That Have a Genetic Alteration
in Anaplastic Lymphoma Kinase (ALK)
Principal Investigator Suzanne Shusterman, MD
- Phase I Study of Olaparib with Irinotecan and/or
Temozolomide in Adolescent and Adult Patients with Recurrent/Metastatic Ewing's
Sarcoma Following Failure of Prior Chemotherapy
Principal Investigator Steven DuBois, MD
Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.